Teaser text

Bionic array Directed Gene Electrotransfer (BaDGE®) is a platform technology for targeted delivery of naked DNA. The first clinical application uses DNA encoding neurotrophins to drive regrowth of the auditory nerve.

Body Text

Competitive advantage

  • First-in-class DNA electro-transfer technology for targeted DNA payload delivery to a broad range of tissue targets. It is:
    • Safe (naked DNA)
    • Regulatory permissive (non-viral)
    • Not limited by gene size packaging constraints
    • The highest level of control of the delivery of genes to target tissues
    • High efficiency gene augmentation therapeutics
  • Multi-disciplinary team working at the interface of biology, engineering and clinical translation
  • A patent portfolio covering all aspects of the BaDGE® platform


  • BaDGE® is broadly transferrable to nerve/ brain injury and muscle re-innervation.
  • Validated for nerve repair and directed nerve regrowth, CNS neuromodulation, control of muscle contraction
  • Broad application potential based on this novel gene electrotransfer technology for discrete targeting of DNA therapeutics in tissues, brain injury, DNA vaccines, oncology, cardiovascular disease, hearing loss, and vision

Successful applications

  • BaDGE® cochlear implant neurotrophin gene therapy clinical trial to regenerate the auditory nerve
  • Licensing agreements with industry partners reflect due diligence on BaDGE® capabilities

Capabilities and facilities

  • DNA therapeutics – models, including cell, tissue and behavioural models, focusing on translational neuroscience applications, including nerve injury, brain injury, hearing and vision, pain, stroke, and traumatic brain injury
  • Biomedical Engineering Faculty allows application-specific modelling, design and DNA delivery probe production

Our partners

  • National and international medical device companies
  • DNA Therapeutics Licensees